| Drug Name |
Idarubicin hydrochloride |
| Drug ID |
BADD_D01128 |
| Description |
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. |
| Indications and Usage |
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01DB06 |
| DrugBank ID |
DB01177
|
| KEGG ID |
D01747
|
| MeSH ID |
D015255
|
| PubChem ID |
636362
|
| TTD Drug ID |
D01XDL
|
| NDC Product Code |
0143-9217; 0143-9306; 0143-9218; 0703-4154; 0013-2576; 0143-9219; 0703-4155; 58623-0027; 77391-003; 0703-4156; 27831-003; 17337-0098; 0013-2586; 0143-9307; 0143-9308; 0013-2596 |
| Synonyms |
Idarubicin | 4-Desmethoxydaunorubicin | 4 Desmethoxydaunorubicin | 4-Demethoxydaunorubicin | 4 Demethoxydaunorubicin | IMI-30 | IMI 30 | IMI30 | NSC-256439 | NSC 256439 | NSC256439 | Idarubicin Hydrochloride | Hydrochloride, Idarubicin |
